Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 3/20 | 0.49 |
| ▸ | KIF11 | P52732 | 3/20 | 0.46 |
| ▸ | ESR1 | P03372 | 2/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ATIC | P31939 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | F7 | P08709 | 1/20 | 0.38 |
| ▸ | F3 | P13726 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28710472 | 0.86 | HSD17B10 (0.56) | HSD17B10PARP1KIF11KDM4EROCK2 | |
| SCHEMBL13244886 | 0.82 | PARP1 (0.48) | HSD17B10PARP1KIF11CHEK1KDM4E | |
| SCHEMBL13267316 | 0.77 | PARP1 (0.43) | HSD17B10PARP1CHEK1KDM4EATIC | |
| SCHEMBL1536413 | 0.76 | PARP1 (0.53) | PARP1CHEK1 | |
| SCHEMBL30673402 | 0.76 | PARP1 (0.53) | PARP1CHEK1 | |
| SCHEMBL16676258 | 0.75 | KDM4E (0.46) | PARP1KIF11CHEK1KDM4EROCK2 | |
| SCHEMBL31719901 | 0.74 | CYP17A1 (0.43) | PARP1CHEK1KDM4EROCK2MAPT | |
| SCHEMBL29355842 | 0.73 | KIF11 (0.65) | HSD17B10KIF11ESR1KDM4EMETAP2 | |
| SCHEMBL45243 | 0.73 | KIF11 (0.65) | HSD17B10KIF11ESR1KDM4EMETAP2 | |
| SCHEMBL13409641 | 0.73 | PARP1 (0.50) | HSD17B10PARP1CHEK1KDM4EATIC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005739-B2 | Quinazolinone and isoquinolinone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2018-06-26 | — | — | US | disclosed |
| US-10005739-B2 | Quinazolinone and isoquinolinone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2018-06-26 | — | — | US | disclosed |
| US-10005739-B2 | Quinazolinone and isoquinolinone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20160272595-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-09-22 | — | — | US | disclosed |
| US-20160272595-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-09-22 | — | — | US | disclosed |
| US-20160272595-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-09-22 | — | — | US | disclosed |
| EP-3061749-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2016-08-31 | — | — | EP | disclosed |
| EP-3061749-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2016-08-31 | — | — | EP | disclosed |
| WO-2015060373-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | 中外製薬株式会社 | 2015-04-30 | — | — | WO | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| EP-2627648-A1 | 17aHYDROXYLASE/C17,20-LYASE INHIBITORS | Novartis AG (CH) | 2013-08-21 | — | — | EP | disclosed |
| WO-2012035078-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012035078-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272595-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | NQO2, SDHA, CYP3A5 | HSD17B10 687/4885PARP1 870/4885KIF11 3227/4885 |
| US-10005739-B2 | Quinazolinone and isoquinolinone derivative | NQO2, SDHA, CYP3A5 | HSD17B10 687/4885PARP1 870/4885KIF11 3227/4885 |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | HSD17B10 10/4885PARP1 2549/4885KIF11 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.